Analyst Price Target is $18.33
▲ +278.79% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Instil Bio in the last 3 months. The average price target is $18.33, with a high forecast of $31.00 and a low forecast of $8.00. The average price target represents a 278.79% upside from the last price of $4.84.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Instil Bio.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.